Back to results
US 2014/0235571 A1Published application
Method for treatment of pulmonary fibrosis
AssigneeGalectin Therapeutics, Inc.
InventorPeter G. Traber
Life of this patent
Estimating the term…
Abstract
Methods and compositions of the invention relate to the treatment of pulmonary fibrosis.
Claims20
A method comprising:
- a. obtaining a composition for parenteral or enteral administration comprising a galacto-rhamnogalacturonate in a pharmaceutical acceptable carrier, and
- b. administering to a subject in need thereof an effective dose of the composition that results in at least one of the following:
- at least 5% reduction of lung edema,
- at least 5% reduction of lung pathology severity scores associated with lung fibrosis,
- at least 5% reduction of lung tissue hydroxyproline accumulation,
- at least 5% reduction of expression of pro-inflammatory proteins,
- at least 5% reduction of expression of fibrogenic proteins,
- wherein the subject in need thereof has at least one of the following:
- a primary or secondary lung fibrotic disease.
6 more elements
A method comprising:
- a. obtaining a composition for parenteral or, enteral administration comprising a galactomannan polysaccharide in a pharmaceutical acceptable carrier, and
- b. administering to a subject in need thereof an effective dose of the composition that results in at least one of the following:
- at least 5% reduction of lung oedema,
- at least 5% reduction of lung pathology associated with lung fibrosis, at least at least 5% reduction of hydroxyproline accumulation,
- at least 5% reduction of expression of pro-inflammatory proteins,
- at least 5% reduction of expression of fibrogenic proteins,
- wherein the subject in need thereof has at least one of the following:
- a primary or secondary lung fibrotic disease.
5 more elements
Dependencies are inferred from the claim text.